On employing a translationally controlled tumor protein-derived protein transduction domain analog for transmucosal delivery of drugs

Bae, Hyun Sook; Lee, Kyunglim

doi:10.1016/j.jconrel.2013.06.010

Cited by 23 publications

(31 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…l -TCTP-PTD 13 was recently found to be a useful vehicle for the delivery of insulin through the nasal membrane (Bae & Lee, 2013 ). In this study, we investigated whether replacing residues in l -TCTP-PTD 13 could further increase the efficiency of drug delivery via the nasal route.…”

Section: Resultsmentioning

confidence: 99%

“…We first evaluated the absorption-enhancing properties of intranasally administered insulin plus l -form TCTP-PTD analog formulations. PTD concentrations were selected based on previous studies (Bae & Lee, 2013 ) and our preliminary experiments (data not shown) in which we determined the optimal molar ratio of insulin to PTD that would enhance nasal insulin absorption. Insulin (1 IU/kg) administered alone intranasally was scarcely detectable in the plasma of rats; a dose more than five times higher was required to achieve measurable plasma insulin levels.…”

Section: Resultsmentioning

confidence: 99%

“…Several variants of TCTP-PTD significantly enhanced the transduction compared with that of the wild-type TCTP-PTD (Kim et al., 2011b ). Among them, TCTP-PTD 13 consisting of l -amino acids (1-MIIFRALISHKK-12), enhanced nasal absorption compared to administration of insulin alone (Bae & Lee, 2013 ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Modification of translationally controlled tumor protein-derived protein transduction domain for improved intranasal delivery of insulin

et al. 2018

Self Cite

View full text Add to dashboard Cite

Carrier peptides, termed protein transduction domains (PTDs), serve as provide promising vehicles for intranasal delivery of macromolecular drugs. A mutant PTD derived from human translationally controlled tumor protein (TCTP-PTD 13, MIIFRALISHKK) was reported to provide enhanced intranasal delivery of insulin. In this study, we tested whether its efficiency could be further improved by replacing amino acids in TCTP-PTD 13 or changing the amino acids in the carrier peptides from the l- to the d-form. We assessed the pharmacokinetics of PTD-mediated transmucosal delivery of insulin in normal rats and the activity of insulin in alloxan-induced diabetic rats. The safety/toxicity profile of the carrier peptides was evaluated based on the release of lactate dehydrogenase (LDH) in nasal wash fluid, body weight changes, and several biochemical parameters. Pharmacokinetic and pharmacodynamic studies showed that the l-form of a double substitution A6L, I8A (MIIFRLLASHKK), designated as l-TCTP-PTD 13M2 was the most effective carrier for intranasal insulin delivery. The relative bioavailability of insulin co-administered intranasally with l-TCTP-PTD 13M2 was 37.1% of the value obtained by the subcutaneous route, which was 1.68-fold higher than for insulin co-administered with l-TCTP-PTD 13. Moreover, co-administration of insulin plus l-TCTP-PTD 13M2 reduced blood glucose levels compared to levels in diabetic rats treated with insulin plus l-TCTP-PTD 13. There was no evidence of toxicity. These results suggest that the newly designed PTD is a useful carrier peptide for the intranasal delivery of drugs or biomolecules.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Modification of translationally controlled tumor protein-derived protein transduction domain for improved intranasal delivery of insulin

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Many researchers recognized protein transduction as a promising vehicle for delivery of macromolecular drugs [16]. It has been widely used in medical experiments [7] [17].…”

Section: Discussionmentioning

confidence: 99%

A Method to Improve the Embryogenesis Rate of Banana Somatic Cell Embryogenesis

Shenghe¹,

Wu²,

Sun³

et al. 2018

AJPS

View full text Add to dashboard Cite

Getting embryogenic callus is the first step for banana transformation. Enhancing embryonic-callus-rate is important for banana molecular breeding. In this paper, WIND1, an AP2/ERF transcription factor was added into the embryonic-callus-inducing medium with poly-Arg and nuclear localization signal (NLS). The embryogenic-callus-induced rate of the immature male florescence cultured on the media containing the recombinant protein Arg9-NLS-WIND1 was significantly higher than that of the immature male florescence cultured on the control media. Medium containing 0.01% of the protein Arg9-NLS-WIND1 had the best effect for inducing the embryogenesis of the immature male inflorescence. On the medium containing 0.01% of the protein Arg9-NLS-WIND1, 11.5% of the immature male flowers can develop embryonic callus. On the medium containing Arg9-NLS-WIND1, the protein might be transferred into cytoplasm of the explants by endocytosis due to the interaction between the poly-Arg transduction domain and the plasma membrane. After it entered the nucleus guided by NLS and bind with the target DNA domain, the somatic cell embryogenesis reactions were initiated and the embryonic callus formed.

show abstract

“…Protein transduction domains (PTD) have been used for the delivery of various biologically active molecules, including protein- and nucleic acid-based molecules. 84 These PTDs could be easily incorporated into T cell transgenes. Additionally, the identification of PTDs that selectively direct therapeutic internalization into tumor cells could enhance therapeutic efficacy.…”

Section: Limitations and Potential Challenges In Producer T Cellsmentioning

confidence: 99%

Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors

Tsai

Dávila

2016

OncoImmunology

View full text Add to dashboard Cite

Adoptive cell transfer (ACT) is an emerging anticancer therapy that has shown promise in various malignancies. Redirecting antigen specificity by genetically engineering T cells to stably express receptors has become an effective variant of ACT. A novel extension of this approach is to utilize engineered T cells to produce and deliver anticancer therapeutics that enhance cytotoxic T cell function and simultaneously inhibit immunosuppressive processes. Here, we review the potential of using T cells as therapeutic-secreting vehicles for immunotherapies and present theoretical and established arguments in support of further development of this unique cell-based immunotherapy.

show abstract

On employing a translationally controlled tumor protein-derived protein transduction domain analog for transmucosal delivery of drugs

Cited by 23 publications

References 26 publications

Modification of translationally controlled tumor protein-derived protein transduction domain for improved intranasal delivery of insulin

Modification of translationally controlled tumor protein-derived protein transduction domain for improved intranasal delivery of insulin

A Method to Improve the Embryogenesis Rate of Banana Somatic Cell Embryogenesis

Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors

Contact Info

Product

Resources

About